Agenus Inc. — Q3 2015 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2015. Agenus is an immunology company developing checkpoint-modulating antibodies, heat-shock-protein vaccines and vaccine adjuvants. Its programs are largely preclinical or dependent on partners; it had no product-sales revenue reported.
Financial performance and liquidity
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $6.8 million | $1.6 million | $17.2 million | $5.4 million |
| Research and development expense | $18.5 million | $5.3 million | $52.5 million | $15.0 million |
| General and administrative expense | $6.4 million | $4.9 million | $19.9 million | $16.2 million |
| Operating loss | $11.1 million | $7.7 million | $62.6 million | $26.0 million |
| Net loss | $13.1 million | $8.1 million | $72.3 million | $16.5 million |
| Net loss per common share | $0.16 | $0.13 | $0.95 | $0.28 |
Revenue primarily reflected Incyte collaboration activity, including development-cost reimbursements and recognition of deferred upfront and other license revenue. The filing does not provide a meaningful operating margin for this loss-making, development-stage business.
- Cash and investments: $199.1 million at September 30, 2015, versus $40.2 million at December 31, 2014. Cash and cash equivalents alone were $184.1 million.
- Cash flow: Operating activities used $27.6 million in the first nine months of 2015, broadly similar to $27.7 million in 2014. Investing activities used $3.3 million; financing activities provided $189.4 million.
- Debt: Principal outstanding was approximately $114.1 million; balance-sheet debt carrying value was $110.7 million. This included $100 million of limited-recourse notes bearing 13.5% interest and $14 million of 8% subordinated notes.
- Balance sheet: Total assets were $242.6 million, current liabilities $28.3 million, and stockholders’ equity $77.0 million. Accumulated deficit was $763.6 million.
Material changes and notable items
- Revenue increased year over year, largely with the Incyte collaboration; Agenus recognized $16.1 million of collaboration revenue during the nine-month period, including amortization of the $25 million upfront payment.
- R&D expense rose sharply, mainly from checkpoint-modulator development, increased third-party services and staffing, one-time technology license fees, and a $13.2 million Celexion asset acquisition expensed as in-process R&D.
- Incyte invested $35 million in Agenus shares, and Agenus received approximately $75 million net from a May public offering.
- In September, Antigenics issued $100 million of limited-recourse notes secured by GSK royalty rights. Agenus reported approximately $78 million of net proceeds in its liquidity discussion; the transaction also involved a $20 million cash payment and 300,000 shares to terminate the prior royalty assignment. The notes accrue 13.5% interest, compounded quarterly; royalty payments are dedicated to servicing them. Agenus and another subsidiary guarantee certain payment obligations.
- In February, Agenus exchanged and issued subordinated notes totaling $14 million, due February 2018, and issued warrants to buy 1.4 million shares.
- Non-operating results included fair-value adjustments to contingent obligations and foreign-exchange effects. The Q3 operating results also included a $7.0 million benefit from the fair-value adjustment to contingent purchase consideration; the nine-month period included a $7.3 million expense from that item.
Outlook, management commentary and risks
- Management estimated existing working capital would fund operations into the first half of 2018, based on current plans. Agenus expects continued losses and may need further partnering, asset sales, debt or equity financing; failure to obtain funding could threaten continued operations.
- The company planned two IND filings in 2015 for checkpoint-modulator candidates and anticipated first clinical trials from its programs in 2016. These were forward-looking plans, not reported achievements in this filing.
- Agenus cited positive Phase 2 Prophage results in newly diagnosed glioblastoma compared with historical controls, while exploring randomized trials and partnering. It cautioned that further development and financing were uncertain. It did not expect to advance HerpV to Phase 3.
- GSK’s shingles and malaria vaccine programs using QS-21 were potential sources of royalties; Agenus said initial QS-21-containing product launches were anticipated around 2017. The company had monetized the related GSK royalties, so those proceeds first service the notes, and future royalties depend on approvals, sales and manufacturing.
- Key risks include clinical and regulatory failure, partner decisions or delays, manufacturing constraints, competition, patent and licensing challenges, foreign-currency exposure, and the high-cost 13.5% royalty-backed financing and its guarantees, put, make-whole and default provisions. Management warned that reduced GSK royalties or payment obligations could harm liquidity.
- Disclosure controls were assessed as effective; the filing reported no material third-quarter change in internal control over financial reporting.
Investor facts to verify
- Whether operating cash use and development spending remain consistent with management’s first-half-2018 liquidity estimate.
- Progress and timing of the stated IND filings, clinical-trial starts, and controlled Prophage studies.
- GSK vaccine approval, launch, sales and royalty performance, and how those proceeds compare with the notes’ interest and repayment terms.
- Future financing needs, dilution from share issuance and outstanding options, warrants and contingent acquisition payments.
- Whether partner commitments, manufacturing capacity and intellectual-property rights support advancement of the pipeline.